HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional) | RFA DA 23 054

Opportunity Information: Apply for RFA DA 23 054

The HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional) funding opportunity (RFA-DA-23-054) is an NIH grant designed to move proven research into real-world settings where it can reduce overdose deaths and improve care at the intersection of pain management and opioid use disorder (OUD). The emphasis is on translational dissemination and implementation (D&I) research, meaning projects should focus less on discovering entirely new treatments and more on figuring out how to adopt, scale, sustain, and improve evidence-based practices in clinics, health systems, community programs, and other service settings. This opportunity sits under the broader Helping to End Addiction Long-term (HEAL) Initiative and is meant to support the HEAL Translation to Practice Team, which is focused on closing the gap between what is known to work and what is actually used in everyday practice.

A key feature of this announcement is that it serves as a "parent" RFA that runs alongside more targeted NIH Notices of Special Interest (NOSIs) that highlight specific priority areas. For fiscal year 2023, the opportunity specifically points to two focus areas that were previously their own RFAs: one centered on workforce needs (the Workforce NOSI) and another centered on the role of violence and trauma (the Violence and Trauma NOSI). In practice, that means applicants can propose broader translation-to-practice projects under the parent RFA while also aligning with the more specific directions NIH releases through these NOSIs. The RFA is also described as operating in tandem with a companion R61/R33 opportunity, signaling that NIH is supporting both phased, milestone-driven projects (R61/R33) and projects that fit the R33 mechanism described here.

The mechanism is R33, and clinical trials are optional, which gives applicants flexibility. Projects may be entirely implementation-focused without a clinical trial, or they may include a trial component when a rigorous evaluation of implementation strategies or health outcomes is appropriate. Regardless of whether a clinical trial is included, the core expectation is that the work is practical and impact-oriented: identifying barriers to uptake, testing strategies to increase adoption and fidelity, improving delivery in diverse settings, strengthening sustainability over time, and ultimately contributing to reduced overdose risk and better outcomes for people experiencing pain, OUD, or both. The overall activity aligns with NIH priorities across education, health, income security, and social services, reflecting the reality that overdose prevention and OUD care often require coordinated approaches that go beyond traditional healthcare alone.

Eligibility is broad and includes many types of U.S.-based organizations and governments. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses. The announcement also calls out additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. At the same time, it clarifies limits related to foreign involvement: non-U.S. organizations and non-U.S. institutions are not eligible to apply, and non-domestic components of U.S. organizations are not eligible. However, "foreign components" (as NIH defines them in the NIH Grants Policy Statement) are allowed, which typically means a U.S. applicant can include certain types of foreign collaborations or activities when justified and approved under NIH policy.

Administratively, the opportunity is offered by the National Institutes of Health under a discretionary grant funding instrument, with CFDA numbers listed as 93.213, 93.242, 93.279, and 93.865. The funding opportunity was created on 2022-08-03, and it was expected to run across two fiscal years (FY23 and FY24). The listed application due date in the provided data is 2024-03-20. The award ceiling is stated as $750,000, which gives a sense of the maximum budget level NIH is willing to consider under this announcement (applicants would still need to follow the specific budget and project period rules in the full RFA). The number of expected awards is not specified in the provided summary, which is common for NIH opportunities when final award counts depend on available appropriations and the quality of the application pool.

In plain terms, this grant is aimed at teams that already know what interventions, care models, or service approaches are evidence-based for overdose prevention, OUD treatment, and pain/OUD overlap, and now want to solve the hard part: making those approaches work reliably in the real world, across different communities, systems, and populations. Competitive applications are likely to be those that are tightly grounded in implementation science, are built with strong practice partners, and show a clear pathway from research findings to measurable improvements in service delivery and overdose-related outcomes.

• The National Institutes of Health in the education, health, income security and social services sector is offering a public funding opportunity titled "HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.213, 93.242, 93.279, 93.865.
• This funding opportunity was created on 2022-08-03.
• Applicants must submit their applications by 2024-03-20. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $750,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DA 23 054

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: